The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

Though new to Brevard County, Dr. Peter Bracha brings more than a decade of experience treating the full range of retinal conditions.

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...